Cargando…
Subnormal GM1 in PBMCs: Promise for Early Diagnosis of Parkinson’s Disease?
The fact that Parkinson’s disease (PD) pathologies are well advanced in most PD patients by the time of clinical elucidation attests to the importance of early diagnosis. Our attempt to achieve this has capitalized on our previous finding that GM1 ganglioside is expressed at subnormal levels in virt...
Autores principales: | Alselehdar, Samar K., Chakraborty, Monami, Chowdhury, Suman, Alcalay, Roy N., Surface, Matthew, Ledeen, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583888/ https://www.ncbi.nlm.nih.gov/pubmed/34768952 http://dx.doi.org/10.3390/ijms222111522 |
Ejemplares similares
-
Systemic deficiency of GM1 ganglioside in Parkinson’s disease tissues and its relation to the disease etiology
por: Ledeen, Robert, et al.
Publicado: (2022) -
The Key Role of GM1 Ganglioside in Parkinson’s Disease
por: Chowdhury, Suman, et al.
Publicado: (2022) -
Synthetic GM1 improves motor and memory dysfunctions in mice with monoallelic or biallelic disruption of GM3 synthase
por: Chowdhury, Suman, et al.
Publicado: (2023) -
Age-Related Decline in Gangliosides GM1 and GD1a in Non-CNS Tissues of Normal Mice: Implications for Peripheral Symptoms of Parkinson’s Disease
por: Chowdhury, Suman, et al.
Publicado: (2023) -
Parkinson’s disease recovery by GM1 oligosaccharide treatment in the B4galnt1(+/−) mouse model
por: Chiricozzi, Elena, et al.
Publicado: (2019)